author-photo

Atish D. Choudhury

Harvard University

76

Papers

2123

Citations

Citation Trend

Filter By

Papers (47) Sort By

Journal Conference Others

Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for oligometastatic prostate cancer

2021 Advances in radiation oncology
Show All
- Source
- Cite
- Save
Citations (0)
Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (1)
A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

2021
Show All
- Source
- Cite
- Save
Citations (18)
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (28)
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

2020 Cancer
Show All
- Source
- Cite
- Save
Citations (7)
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)